Top

Published in:

01-06-2015

Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB

Authors: Qian Zhang, Fan Yang, Xun Li, Lu-wen Wang, Xiao-gang Chu, Hong Zhang, Zuo-jiong Gong

Published in: Inflammation | Issue 3/2015

Abstract

Histone deacetylase inhibitors (HDACi) were recently shown to suppress inflammatory responses in experimental models of autoimmune and inflammatory diseases. In this study, the protective effects of Trichostatin A (TSA), an HDACi, on experimental acute-on-chronic liver failure (ACLF) in rat were explored. An ACLF model was established in rats, and animals were randomly divided into control, model, and TSA-treated groups. The rats in TSA-treated group received TSA (2 mg/kg) at 2 h before induction of ACLF. Samples were obtained at 24 h after ACLF induction. We found that the rats in model group showed severe damage to liver tissue at 24 h after ACLF induction. TSA improved liver injury effectively. Serum tumor necrosis factor-alpha (TNF-α), interferon-γ (IFN-γ), interleukin (IL)-10, and IL-18 levels were significantly increased in model group compared with control group, but TSA reduced serum TNF-α, IFN-γ, IL-10, and IL-18 levels effectively compared with model group. In addition, TSA reduced the total HDAC activity, promoted the acetylation of histone, and decreased the expressions of class I HDAC in liver tissue. TSA also increased the acetylation levels and decreased phosphorylation levels in NF-κB p65. The median survival time of the rats was significantly prolonged in TSA-treated group. To conclude, TSA can inhibit the release of multiple inflammatory cytokines, prolong the survival time, and protect against ACLF in rats. The mechanisms were probably through enhancing the acetylation levels of non-histones rather than histone.

Jalan, R., and R. Williams. 2002. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 20(3): 252–261.CrossRefPubMed

Wells, C.A., T. Ravasi, G.J. Faulkner, P. Carninci, Y. Okazaki, Y. Hayashizaki, M. Sweet, B.J. Wainwright, and D.A. Hume. 2003. Genetic control of the innate immune response BMC. Immunol 4: 5.

Wells, C.A., T. Ravasi, R. Sultana, K. Yagi, P. Carninci, H. Bono, G. Faulkner, Y. Okazaki, J. Quackenbush, D.A. Hume, and Lyons PA; RIKEN GER Group; GSL Members. 2003. Continued discovery of transcriptional units expressed in cells of the mouse mononuclear phagocyte lineage. Genome Res 13(6B): 1360–1365.CrossRefPubMedCentralPubMed

Byl, B., I. Roucloux, A. Crusiaux, E. Dupont, and J. Deviere. 1993. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 104: 1492–1497.PubMed

Le Moine, O., J. Devière, J.M. Devaster, A. Crusiaux, F. Durand, J. Bernuau, M. Goldman, and J.P. Benhamou. 1994. Interleukin-6: an early marker of bacterial infection indecompensated cirrhosis. J Hepatol 20: 819–824.CrossRefPubMed

Navasa, M., A. Follo, X. Filella, W. Jiménez, A. Francitorra, R. Planas, A. Rimola, V. Arroyo, and J. Rodés. 1998. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 27(5): 1227–1232.CrossRefPubMed

Genesca, J., A. Gonzalez, R. Segura, R. Catalan, R. Marti, E. Varela, G. Cadelina, M. Martinez, J.C. Lopez-Talavera, R. Esteban, R.J. Groszmann, and J. Guardia. 1999. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 94(1): 169–177.CrossRefPubMed

Rodríguez-Ramos, C., F. Galan, F. Díaz, J. Elvira, L. Martín-Herrera, and J.A. Girón-González. 2001. Expression of pro-inflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Dig Dis Sci 46(8): 1668–1676.CrossRefPubMed

Albillos, A., L. Hera Ad Ade, E. Reyes, J. Monserrat, L. Muñoz, M. Nieto, A. Prieto, E. Sanz, and M. Alvarez-Mon. 2004. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: Amelioration with norfloxacin. J Hepatol 40: 624–631.CrossRefPubMed

10.

Rolando, N., J. Wade, M. Davalos, J. Wendon, J. Philpott-Howard, and R. Williams. 2000. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32(4 Pt 1): 734–739.CrossRefPubMed

11.

Albillos, A., A. de la Hera, M. González, J.L. Moya, J.L. Calleja, J. Monserrat, L. Ruiz-del-Arbol, and M. Alvarez-Mon. 2003. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37(1): 208–217.CrossRefPubMed

12.

Harry, R., G. Auzinger, and J. Wendon. 2002. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 36: 395–402.CrossRefPubMed

13.

Kawai, T., and S. Akira. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 1143: 1–20.CrossRefPubMed

14.

Serhan, C.N., N. Chiang, and T.E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5): 349–361.CrossRefPubMedCentralPubMed

15.

Berger, S.L. 2007. The complex language of chromatin regulation during transcription. Nature 447(7143): 407–412.CrossRefPubMed

16.

Dolinoy, D.C., J.R. Weidman, and R.L. Jirtle. 2007. Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod Toxicol 23(3): 297–307.CrossRefPubMed

17.

Jirtle, R.L., and M.K. Skinner. 2007. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8(4): 253–262.CrossRefPubMed

18.

Khan, N., M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S.C. Berghs, N. Carey, P.W. Finn, L.S. Collins, A. Tumber, J.W. Ritchie, P.B. Jensen, H.S. Lichenstein, and M. Sehested. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409(2): 581–589.CrossRefPubMed

19.

Blanchard, F., and C. Chipoy. 2005. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10(3): 197–204.CrossRefPubMed

20.

Gray, S.G., and T.J. Ekström. 2001. The human histone deacetylase family. Exp Cell Res 262(2): 75–83.CrossRefPubMed

21.

Lin, T., H.B. Alam, H. Chen, J. Britten-Webb, P. Rhee, J. Kirkpatrick, and E. Koustova. 2006. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery 139(3): 365–376.CrossRefPubMed

22.

Gonzales, E., H. Chen, R. Munuve, T. Mehrani, J. Britten-Webb, A. Nadel, H.B. Alam, D. Wherry, D. Burris, and E. Koustova. 2006. Valproic acid prevents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones. Shock 25(4): 395–401.CrossRefPubMed

23.

Li, Y., B. Liu, H. Zhao, E.A. Sailhamer, E.Y. Fukudome, X. Zhang, T. Kheirbek, R.A. Finkelstein, G.C. Velmahos, M. De Moya, C.A. Hales, and H.B. Alam. 2009. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock 32(5): 517–523.CrossRefPubMed

24.

Lin, T., H. Chen, E. Koustova, E.A. Sailhamer, Y. Li, C. Shults, B. Liu, P. Rhee, J. Kirkpatrick, and H.B. Alam. 2007. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery 141(6): 784–794.CrossRefPubMed

25.

Cao, W., C. Bao, E. Padalko, and C.J. Lowenstein. 2008. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med 205(6): 1491–1503.CrossRefPubMedCentralPubMed

26.

Zhang, L., J. Wan, R. Jiang, W. Wang, H. Deng, Y. Shen, W. Zheng, and Y. Wang. 2009. Protective effects of trichostatin A on liver injury in septic mice. Hepatol Res 39(9): 931–938.CrossRefPubMed

27.

Winkler, A.R., K.N. Nocka, and C.M. Williams. 2012. Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production. Pulm Pharmacol Ther 25(4): 286–292.CrossRefPubMed

28.

Wang, L.W., L.K. Wang, H. Chen, F. Cheng, X. Li, C.M. He, and Z.J. Gong. 2012. Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats. World J Gastroenterol 18(40): 5709–5718.CrossRefPubMedCentralPubMed

29.

Yang, X.J., and E. Seto. 2008. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 31(4): 449–461.CrossRefPubMedCentralPubMed

30.

Yang, X.J., and E. Seto. 2007. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37): 5310–5318.CrossRefPubMed

31.

Halili, M.A., M.R. Andrews, M.J. Sweet, and D.P. Fairlie. 2009. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 9(3): 309–319.CrossRefPubMed

32.

Okamoto, H., Y. Fujioka, A. Takahashi, T. Takahashi, T. Taniguchi, Y. Ishikawa, and M. Yokoyama. 2006. Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb 13(4): 183–191.CrossRefPubMed

33.

Yu, Z., W. Zhang, and B.C. Kone. 2002. Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol 13(8): 2009–2017.CrossRefPubMed

34.

Suuronen, T., J. Huuskonen, R. Pihlaja, S. Kyrylenko, and A. Salminen. 2003. Regulation ofmicroglial inflammatory response by histone deacetylase inhibitors. J Neurochem 87(2): 407–416.CrossRefPubMed

35.

Moreau R, Arroyo V. Acute on chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol. 2014 Feb 28. [Epub ahead of print]

36.

Li, X., L.K. Wang, L.W. Wang, X.Q. Han, F. Yang, and Z.J. Gong. 2013. Blockade of high-mobilitygroup box-1 ameliorates acute on chronic liver failure in rats. Inflamm Res 62(7): 703–709.CrossRefPubMed

37.

Zou, Z., B. Li, D. Xu, Z. Zhang, J.M. Zhao, G. Zhou, Y. Sun, L. Huang, J. Fu, Y. Yang, L. Jin, W. Zhang, J. Zhao, Y. Sun, S. Xin, and F.S. Wang. 2009. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol 43(2): 182–190.CrossRefPubMed

38.

Choi, J.H., S.W. Oh, M.S. Kang, H.J. Kwon, G.T. Oh, and D.Y. Kim. 2005. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35(1): 89–96.CrossRefPubMed

39.

Glauben, R., A. Batra, I. Fedke, M. Zeitz, H.A. Lehr, F. Leoni, P. Mascagni, G. Fantuzzi, C.A. Dinarello, and B. Siegmund. 2006. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176(8): 5015–5022.CrossRefPubMed

40.

Lin, H.S., C.Y. Hu, H.Y. Chan, et al. 2007. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collageninduced arthritis in rodents. Br J Pharmacol 150: 862–872.CrossRefPubMedCentralPubMed

41.

Berger, S.L. 2002. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12(2): 142–148.CrossRefPubMed

42.

Marinova, Z., M. Ren, J.R. Wendland, Y. Leng, M.H. Liang, S. Yasuda, P. Leeds, and D.M. Chuang. 2009. Valproic acid induces functional heat-shock protein 70 via class I histonedeacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 111(4): 976–987.CrossRefPubMedCentralPubMed

43.

Nasu, Y., K. Nishida, S. Miyazawa, T. Komiyama, Y. Kadota, N. Abe, A. Yoshida, S. Hirohata, A. Ohtsuka, and T. Ozaki. 2008. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in acollagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16(6): 723–732.CrossRefPubMed

44.

Sailhamer, E.A., Y. Li, E.J. Smith, F. Shuja, C. Shults, B. Liu, C. Soupir, M. De Moya, G. Velmahos, and H.B. Alam. 2008. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery 144(2): 204–216.CrossRefPubMed

45.

Leoni, F., G. Fossati, E.C. Lewis, J.K. Lee, G. Porro, P. Pagani, D. Modena, M.L. Moras, P. Pozzi, L.L. Reznikov, B. Siegmund, G. Fantuzzi, C.A. Dinarello, and P. Mascagni. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11(1–12): 1–15.CrossRefPubMedCentralPubMed

46.

Choudhary, C., C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen, and M. Mann. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942): 834–840.CrossRefPubMed

47.

McKinsey, T.A., and E.N. Olson. 2004. Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp 259: 132–141.CrossRefPubMed

48.

Cao, W., C. Bao, E. Padalko, and C.J. Lowenstein. 2008. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits toll-like receptor signaling. J Exp Med 205: 1491–1503.CrossRefPubMedCentralPubMed

49.

Chen, L., W. Fischle, E. Verdin, and W.C. Greene. 2001. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653–1657.CrossRef

50.

Chen, L.F., and W.C. Greene. 2003. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 81: 549–557.CrossRefPubMed

Title: Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB
Authors: Qian Zhang
Fan Yang
Xun Li
Lu-wen Wang
Xiao-gang Chu
Hong Zhang
Zuo-jiong Gong
Publication date: 01-06-2015
Publisher: Springer US
Published in: Inflammation / Issue 3/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-014-0108-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

The Anti-inflammatory Effect of the CXCR4 Antagonist-N15P Peptide and Its Modulation on Inflammation-Associated Mediators in LPS-Induced PBMC

Mesenteric Lymph Duct Drainage Attenuates Acute Lung Injury in Rats with Severe Intraperitoneal Infection

In Vitro Oxidation of Fibrinogen Promotes Functional Alterations and Formation of Advanced Oxidation Protein Products, an Inflammation Mediator

Effects of Resveratrol on the Treatment of Inflammatory Response Induced by Severe Burn

I n Vitro Anti-inflammatory and Immunomodulatory Effects of Ciprofloxacin or Azithromycin in Staphylococcus aureus-Stimulated Murine Macrophages are Beneficial in the Presence of Cytochalasin D

Investigation of the Anti-Inflammatory Effects of Safranal on High-Fat Diet and Multiple Low-Dose Streptozotocin Induced Type 2 Diabetes Rat Model

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page